UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 73

Sortiert nach

Targeting MET amplification in EGFR-mutant non-small-cell lung cancer

The lancet respiratory medicine, 2020-11, Vol.8 (11), p.1068-1070

2020

Volltextzugriff (PDF)

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies

Cancers, 2020-06, Vol.12 (6), p.1475

2020

Volltextzugriff (PDF)

BRCA1: a novel prognostic factor in resected non-small-cell lung cancer

PloS one, 2007-11, Vol.2 (11), p.e1129-e1129

2007

Volltextzugriff (PDF)

Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

Frontiers in oncology, 2020-09, Vol.10, p.1726-1726

2020

Volltextzugriff (PDF)

Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma

Cell communication and signaling, 2019-10, Vol.17 (1), p.137-137, Article 137

2019

Volltextzugriff (PDF)

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression

PloS one, 2009-05, Vol.4 (5), p.e5133-e5133

2009

Volltextzugriff (PDF)

Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung

Clinical cancer research, 2008-08, Vol.14 (15), p.4794-4799

2008

Volltextzugriff (PDF)

Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines

Translational lung cancer research, 2019-08, Vol.8 (4), p.340-351

2019

Volltextzugriff (PDF)

Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma

JTO clinical and research reports, 2020-11, Vol.1 (4), p.100084-100084, Article 100084

2020

Volltextzugriff (PDF)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib

JTO clinical and research reports, 2021-03, Vol.2 (3), p.100113-100113, Article 100113

2021

Volltextzugriff (PDF)

Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening

EBioMedicine, 2015-08, Vol.2 (8), p.782-783

2015

Volltextzugriff (PDF)

Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer

Pharmacological research, 2021-08, Vol.170, p.105701-105701, Article 105701

2021

Volltextzugriff (PDF)

KRAS inhibitors, approved

Nature cancer, 2021-12, Vol.2 (12), p.1254

2021

Volltextzugriff (PDF)

Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy

Expert opinion on biological therapy, 2019-05, Vol.19 (5), p.457-467

2019

Volltextzugriff (PDF)

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

JNCI : Journal of the National Cancer Institute, 2017-09, Vol.109 (9)

2017

Volltextzugriff (PDF)

Abstract 4294: An integrative project for tracing the genes involved in depression and cancer (DeCa) in peripheral blood

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4294-4294

2020

Volltextzugriff (PDF)

Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma

Lung cancer (Amsterdam, Netherlands), 2020-02, Vol.140, p.42-45

2020

Volltextzugriff (PDF)

SRC-homology 2 domain-containing phosphatase 2 (SHP2) in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9540-9540

2020

Volltextzugriff (PDF)

Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer

Expert review of clinical pharmacology, 2019-09, Vol.12 (9), p.831-840

2019

Volltextzugriff (PDF)

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)

Oncotarget, 2017-07, Vol.8 (29), p.47305-47316

2017

Volltextzugriff (PDF)

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)

EBioMedicine, 2019-01, Vol.39, p.207-214

2019

Volltextzugriff (PDF)

The C‐terminal domain of the heavy chain of tetanus toxin rescues cerebellar granule neurones from apoptotic death: involvement of phosphatidylinositol 3‐kinase and mitogen‐activated protein kinase pathways

Journal of neurochemistry, 2004-09, Vol.90 (5), p.1227-1236

2004

Volltextzugriff (PDF)

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2019-02, Vol.14 (2), p.304-310

2019

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(38)
Life Sciences & Biomedicine
(34)
Oncology
(21)
Humans
(18)
Lung Cancer
(12)
Female
(11)
Respiratory System
(11)
Carcinoma, Non-Small-Cell Lung - Genetics
(9)
Lung Neoplasms - Genetics
(9)
Male
(9)
Aged
(8)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(8)
Middle Aged
(8)
Non-Small Cell Lung Cancer
(8)
Carcinoma, Non-Small-Cell Lung - Pathology
(7)
Egfr
(7)
Lung Neoplasms - Pathology
(7)
Mutation
(7)
Animals
(6)
Erbb Receptors - Genetics
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Targeting MET amplification in EGFR-mutant non-small-cell lung cancer

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies

BRCA1: a novel prognostic factor in resected non-small-cell lung cancer

Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression

Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung

Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines

Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib

Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening

Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer

KRAS inhibitors, approved

Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

Abstract 4294: An integrative project for tracing the genes involved in depression and cancer (DeCa) in peripheral blood

Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma

Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

SRC-homology 2 domain-containing phosphatase 2 (SHP2) in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD)

Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)

The C‐terminal domain of the heavy chain of tetanus toxin rescues cerebellar granule neurones from apoptotic death: involvement of phosphatidylinositol 3‐kinase and mitogen‐activated protein kinase pathways

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

Suchergebnisse filtern